Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02795897 · ClinicalTrials.gov registry record
Genomic Translation for Amyotrophic Lateral Sclerosis Care
A clinical trial, sponsored by Columbia University.
- Completed
- Registry status
- 254
- Enrollment target
NCT02795897: Completed study, sponsored by Columbia University.
NCT02795897 is a clinical trial that has completed, run by Columbia University. The registered enrollment target is 254 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02795897 has completed, sponsored by Columbia University.
- COMPLETED
- Registry status
- 254 participants
- Enrollment target
Study Summary
The purpose of this study is to look for abnormal genes and gene expression profiles that help determine why a person develops amyotrophic lateral sclerosis (ALS) and related motor neuron diseases (MND) and why their symptoms present and progress with a particular pattern.
Primary Outcome
Because subjects are followed over their entire disease course and undergo whole genome sequencing of their DNA, this project will study the distinct features (progression and particular symptoms) of subjects with and without mutations in already known ALS genes.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 254 participants |
| Start Date | 2016-06-08 |
| Est. Completion | 2022-06-29 |
What the finished NCT02795897 record still lists
NCT02795897 is an observational study that tracks outcomes without assigning an intervention. The registered 254 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT02795897 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02795897 about?
NCT02795897 is a clinical study titled "Genomic Translation for Amyotrophic Lateral Sclerosis Care". The purpose of this study is to look for abnormal genes and gene expression profiles that help determine why a person develops amyotrophic lateral sclerosis (ALS) and related motor neuron diseases (MND) and why their symptoms present and progress with a particular pattern.
What is the current status of trial NCT02795897?
This trial is currently completed. The enrollment target is 254 participants. The study started on 2016-06-08. Estimated completion is 2022-06-29.
Who is sponsoring clinical trial NCT02795897?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04390737 · 254 participants · Phase 1
Evaluate the Safety and Clinical Activity of HH2853
- NCT04677647 · 254 participants · NA
OurChild: A Health IT Solution to Reduce Minority Health Disparities
- NCT05503797 · 254 participants · Phase 2
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- NCT06167317 · 254 participants · Phase 1
Study of GS-0201 Alone and in Combination in Participants With Advanced Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI